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Abstract
Background: Emphysema is characterised by distinct pathological sub-types, but little is known about the
divergent underlying aetiology. Matrix-metalloproteinases (MMPs) are proteolytic enzymes that can degrade
the extracellular matrix and have been identified as potentially important in the development of emphysema.
However, the relationship between MMPs and emphysema sub-type is unknown. We investigated the role of MMPs
and their inhibitors in the development of emphysema sub-types by quantifying levels and determining
relationships with these sub-types in mild-moderate COPD patients and ex/current smokers with preserved lung
function.
Methods: Twenty-four mild-moderate COPD and 8 ex/current smokers with preserved lung function underwent
high resolution CT and distinct emphysema sub-types were quantified using novel local histogram-based
assessment of lung density. We analysed levels of MMPs and tissue inhibitors of MMPs (TIMPs) in bronchoalveolar
lavage (BAL) and assessed their relationship with these emphysema sub-types.
Results: The most prevalent emphysema subtypes in COPD subjects were mild and moderate centrilobular (CLE)
emphysema, while only small amounts of severe centrilobular emphysema, paraseptal emphysema (PSE) and
panlobular emphysema (PLE) were present. MMP-3, and -10 associated with all emphysema sub-types other
than mild CLE, while MMP-7 and -8 had associations with moderate and severe CLE and PSE. MMP-9 also had
associations with moderate CLE and paraseptal emphysema. Mild CLE occurred in substantial quantities irrespective
of whether airflow obstruction was present and did not show any associations with MMPs.
Conclusion: Multiple MMPs are directly associated with emphysema sub-types identified by CT imaging, apart
from mild CLE. This suggests that MMPs play a significant role in the tissue destruction seen in the more severe
sub-types of emphysema, whereas early emphysematous change may be driven by a different mechanism.
Trial registration: Trial registration number NCT01701869.
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Background
Emphysema is a key feature of chronic obstructive
pulmonary disease (COPD) and contributes directly to
airflow obstruction. It is defined as an abnormal per-
manent enlargement of air spaces distal to the terminal
bronchioles, accompanied by destruction of alveolar
walls [1]. Three distinct pathological sub-types of em-
physema are classified according to the distribution
around the secondary pulmonary lobule and are termed
centrilobular (CLE), panlobular (PLE) and paraseptal
(PSE) emphysema [1]. All sub-types are found in COPD
patients [2, 3] although how they are distributed in indi-
viduals and populations and hence contribute to the dis-
ease is uncertain. CLE is the commonest form [3, 4] and
is associated with older age [4], smoking history [4, 5]
and lower FEV1 [3, 5]. PLE is common in younger age
[4] and is associated with lower BMI [3, 5] and more se-
vere GOLD stage [3]. PSE is the least common form and
is associated with male sex [3], older age, worse respira-
tory symptoms and interstitial abnormalities [6].
Efforts have been made to study emphysema in more
objective detail using CT image analysis and threshold-
based quantification methods, such as %LAA<-950 are
the current standard [7]. These techniques do not pro-
vide any information about emphysema sub-types,
whereas local histogram-based emphysema (LHE) quan-
tification is a novel method, which uses regional histo-
gram data to quantify different emphysema sub-types on
CT images [2]. This analysis has shown stronger associa-
tions with physiological and functional measures of dis-
ease than %LAA<-950 [2]. However, limited work has
assessed the relationship between emphysema sub-types
and underlying mechanisms of disease and consequently
our understanding of the aetiology of these sub-types is
poor. PLE in the context of alpha-1-antitrypsin defi-
ciency (A1ATD), is perhaps the most well understood as
it is the predominant sub-type in this condition where it
is encoded by the Serpina 1 gene, resulting in unopposed
neutrophil elastase activity [8]. In subjects without
A1ATD, PLE has been linked with polymorphisms of the
Serpina 2 gene [9], whilst CLE has been associated with
matrix metalloproteinase-9 (MMP-9) and Transforming
growth factor-β (TGF- β) polymorphisms [10] and PSE
with tissue inhibitor of MMP-2 (TIMP-2) and tumour
necrosis factor (TNF) polymorphisms [10].
There is growing evidence that proteases such as
matrix metalloproteinases (MMPs) are important in the
aetiology of emphysema. Animal models suggest a role
for MMP-1 [11], -9 and -12 [12] in emphysema develop-
ment while human studies demonstrate increased ex-
pression of MMP-1 [13–15], - 2 [15], -3 [15], -8 [14–16],
-9 [13–19], -10 [15] and -12 [13, 20, 21] in the airways
of COPD subjects. We have previously reported MMP-
3, -7 and -10 were associated with overall quantitative
measures of emphysema [15] while Chaudhuri found
MMP-9 and -12 were associated with this measure
[17, 20]. We have also previously shown that MMP-3, -7,
-8, -9, -10 and -12 were associated with CT markers of
small airways disease, but MMPs were not associated with
bronchial wall thickening of the larger airways [15].
Despite the evidence linking MMPs to COPD globally, the
specific role of MMPs in the different emphysema sub-
types have not been investigated. A further complicating
factor in understanding the role of MMPs in emphysema
is the role of proteinase inhibitors. MMPs are tightly
regulated by endogenous inhibitors, the four Tissue inhib-
itors of MMPs (TIMPs) [22]. Sputum MMP-9/TIMP-1 ra-
tio has been found to be significantly raised in COPD [19],
although other studies do not show increased airway
ratios of MMPs/TIMPs [13, 20, 23].
In this study we used novel CT analysis of LHE
patterns to systematically characterise emphysema sub-
types in COPD subjects and ex/current smokers with
preserved lung function. We combined this analysis with
multiplex profiling of MMPs and TIMPs in bronchoalve-
olar lavage (BAL) fluid to further understand the com-
plex relationship between these enzymes and inhibitors
in the initiation and development of emphysema. Under-
standing specific mechanisms driving emphysema is a
key step in the stratification of fundamental COPD
pathology and provides a route into developing new
therapies targeting particular disease endotypes.
Methods
Subjects
Subjects gave written informed consent and the study
(ClinicalTrials.gov:NCT01701869) was approved by
the South Central-Southampton B NRES Committee
(12/SC/0304).
The methods have been described in detail previously
[15]. Twenty-four subjects with mild-moderate COPD as
defined by GOLD guidelines [24] were recruited. Post-
bronchodilator spirometry was used to assess airflow
obstruction with a FEV1/FVC ratio of <0.7 and an FEV1
of ≥50 % predicted value required. Eight current or ex-
smokers with preserved lung function were also re-
cruited. Subjects had at least a 10 pack year smoking
history and exclusion criteria included a history of other
pulmonary disease, long-term antibiotics/steroids or an
exacerbation within the month prior to recruitment.
CT scanning and quantitative image analysis
Subjects underwent volumetric CT scans of the chest in
full inspiration using a Siemens Sensation 64 scanner.
The imaging protocol consisted of; slice thickness
0.75 mm, slice separation 0.5 mm, tube voltage 120KV,
effective mAs 90mAs (using dose modulation), collima-
tion 0.6 mm and a pitch of 1. Images reconstructed with
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the B30 kernel were used for image analysis by custom
software to characterise the emphysema pattern using
local histogram information as previously described [2].
Briefly, regions of interest of size 24.18 × 24.18 mm2
were detected and automatically classified into one of
six categories; non-emphysematous (NE), centrilobular
emphysema by increasing severity (mild CLE, moderate
CLE and severe CLE), panlobular emphysema (PLE) and
paraseptal emphysema (PSE). This was applied to each
CT scan, generating six continuous measures represent-
ing the lung volume percentage that was classified into
each of the six patterns.
Bronchoscopy
In each subject two lobes were targeted at bronchoscopy.
These lobes were determined prior to the procedure by a
thoracic radiologist reporting the lobes most and least af-
fected by disease. BAL was performed by instilling 100 ml
of 0.9 % saline into each lobe and recovered by aspiration.
BAL fluid was filtered and centrifuged and the resultant
supernatant was stored at −80 °C prior to analysis.
MMP and TIMP analysis
MMP and TIMP concentrations in BAL were quantified
using a microparticle based multiplex immunoassay
(R&D systems, Abingdon, UK) and analysed on the
Luminex 200 platform (Biorad Bioplex 200, Hemel
Hempstead, UK). We analysed MMP-3, -7, -8, -9, -10 and
-12 as we had previously linked these to CT parameters of
disease [15] as well as TIMP 1–4 (Additional file 1).
Statistical analysis
Analyses were performed using SPSS version 22.
Mann-Whitney U and Fishers Exact tests compared
data between groups. Associations between MMPs,
spirometry and CT parameters were analysed using
Spearman’s Correlation. Each subject had two lobes
sampled and the mean concentrations between the
lobes were used. For the purpose of statistical analysis,
values that were below the lower limit of detection
were given the value of half the concentration of detec-
tion. A p-value of <0.05 was considered statistically
significant.
Results
Groups were well matched for age, gender and smoking
status (Table 1).
Emphysema sub-types
CT analysis defining specific emphysema sub-types was
successfully achieved in 31 subjects. Figure 1 shows a
typical LHE reconstruction of a subject with COPD and
preserved lung function. One scan from a subject with
preserved lung function could not be analysed for tech-
nical reasons.
All subjects (COPD and preserved lung function) had
non-emphysematous tissue, mild CLE, moderate CLE
and PSE. Only eight subjects had >1 % of PLB. 10
subjects had >1 % of severe CLE. Non-emphysematous
tissue was the most common in 15 subjects. Mild CLE
was the most common in 12 subjects and moderate
CLE the most common in 4 subjects.
The median percentage of each LHE pattern is shown in
Table 1. Moderate CLE, severe CLE, PLE and PSE were all
significantly raised in COPD subjects compared to
those with preserved lung function. Non-emphysematous
tissue was significantly higher in those with preserved
lung function. Median percentage for mild CLE was
over 30 % for subjects with and without airflow obstruc-
tion with no significant difference between the two.
There were significant associations between FEV1 %
predicted and moderate CLE (rho −0.39, p0.032) and
severe CLE (rho −0.37, p0.044). There were no associa-
tions between FEV1 % predicted and mild CLE (rho 0.07,
p0.695), panlobular (rho −0.30, p0.097), paraseptal ( −0.31,
p0.094) or NE (rho 0.32, p0.075).
MMP and TIMP concentrations
We previously reported significantly raised concentra-
tions of MMP-3, -8, -9 and -10 in COPD [15]. TIMP-1
and -2 were found in abundant concentrations within
BAL (Fig. 2), while TIMP-4 was found in lower concen-
trations. TIMP-2 and -4 were significantly increased in
COPD subjects while there was no significant difference
between groups for TIMP-1 and TIMP-3.
Table 1 Characteristics of participants included in the study
COPD (n = 24) Preserved lung
function (n = 8)
P value
Age 66.0 (12.0) 56.0 (18.0) 0.064
Male 16 6 >0.999
Current smoker 11 5 0.685
Pack Years 39 (39.8) 32.25 (23.8) 0.268
FEV1 % predicted 69.00 (21.0) 108.00 (20.3) <0.001*
FEV1/FVC 54.50 (10.8) 78.00 (9.5) <0.001*
Mild CLE 33.8 (8.3) 31.9 (9.5) 0.44
Moderate CLE 21.3 (15.3) 7.1 (9.2) 0.008*
Severe CLE 0.9 (2.0) 0.0 (0.0) 0.008*
Panlobular 2.7 (1.1) 0.0 (0.0) 0.048*
Paraseptal 6.9 (3.9) 3.7 (3.0) 0.014*
Non-emphysema 34.6 (20.6) 53.5 (21.4) 0.011*
Values are given as medians (IQR). Tissue sub-types given as median % of CT
lung volume classified as particular sub-type
Male and current smokers given as number of subjects
Tissue sub-types given for 31 subjects
*p < 0.05. Fisher’s exact test for male and current smoker. Mann-Whitney U-test
for all other variables
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Emphysema sub-types and MMPs and TIMPs
We performed a systematic analysis of associations be-
tween emphysema sub-types and MMP and TIMP BAL
concentrations in the whole cohort. MMP-3 and -10 had
significant associations with all emphysema sub-types
apart from mild CLE. MMP -7 and -8 had significant
associations with all emphysema sub-types apart from
mild CLE and PLE (Table 2). MMP-9 had significant
associations with moderate CLE and PSE. MMP-12 did
not exhibit any significant associations with emphysema
sub-types. TIMP-4 had significant associations with
moderate and severe CLE and PSE. No other TIMPs had
associations with emphysema sub-types (Table 3).
MMPs/TIMPs ratios and emphysema sub-types
To understand the role of a proteinase/antiproteinase
imbalance we investigated the MMP/TIMP ratios. Ratios
were significantly increased in COPD subjects for MMP-
8/TIMP-1, -2, -3, -4, MMP-9/TIMP-1 and MMP-10/
TIMP-1 and -2 (Additional file 1).
Fig. 2 BAL expression of TIMPs in subjects with COPD and preserved lung function. a TIMP-1 (b) TIMP-2 (c) TIMP-3 (d) TIMP-4. Data represents
median upper and lower quartiles. Each dot represents BAL concentration of individual MMP in a specific patient, n = 24 for COPD and 8 for
preserved lung function. * p < 0.05 using Mann-Whitney U test
Fig. 1 Local histogram emphysema (LHE) classification results for a coronal, sagittal and axial slice corresponding to (a) COPD subject and (b) subject
with preserved lung function
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We also investigated associations between emphysema
sub-types and MMP/TIMP ratios (Tables 4, 5, 6 and 7).
Mild CLE did not have any significant associations with
MMP/TIMP ratios. Multiple MMP/TIMP ratios had
associations with all the other tissue sub-types.
Discussion
Using LHE patterns analysed on HRCT images, we
successfully measured emphysema sub-types in mild/
moderate COPD subjects and ex/current smokers with
preserved lung function. The most prevalent tissue sub-
types in COPD subjects were mild and moderate CLE
and non-emphysematous tissue, whilst severe CLE, PSE
and PLE were less frequently present. Furthermore, all
emphysema sub-types, apart from mild CLE, had associ-
ations with multiple MMPs, particularly the stromelysins
MMP-3 and MMP-10, implicating these proteases in the
tissue destruction that occurs in these sub-types of em-
physema. Interestingly, mild CLE was found in substan-
tial quantities in subjects with and without airflow
obstruction and exhibited different properties from the
other sub-types of emphysema showing no associations
with MMPs.
Emphysema is an important pathological feature of
COPD, contributing directly to airflow obstruction
and is associated with mortality and worse outcomes
[25–27]. LHE CT analysis determines the distribution of
the three main emphysema sub-types throughout the
lungs and shows stronger associations with physiological
and functional measures than current CT emphysema
estimation (%LAA<-950) [2]. In our mild-moderate COPD
subjects, the predominant emphysema sub-types were
mild and moderate CLE, with only small quantities of
severe CLE present, which is in keeping with previous
work [2, 3]. CLE is an abnormal enlargement of air-spaces
centred on the respiratory bronchiole and is the classical
form associated with smoking [3, 5]. Only small amounts
of PLE and PSE were present in COPD subjects which
is consistent with other studies [2, 3, 6]. Panlobular
emphysema is an abnormal enlargement of airspaces
distributed throughout the pulmonary lobule and has
been associated with A1ATD and more severe disease
[3, 5]. It is therefore unsurprising that PLE was found
in such low quantities in our cohort. Paraseptal emphy-
sema refers to emphysematous change adjacent to a
pleural surface and is the least well understood form of
emphysema and shows no relationship with COPD
symptoms [3] or smoking history [4].
The underlying mechanisms driving the evolution of
emphysema sub-types are poorly understood. MMPs are
proteolytic enzymes implicated in the destruction of
the pulmonary extra-cellular matrix (ECM). We have
Table 2 Spearman’s correlation analysis between MMPs and
emphysema sub-types
MMP-3 MMP-7 MMP-8 MMP-9 MMP-10 MMP-12
Mild CLE −0.09 −0.11 −0.10 −0.8 0.05 −0.30
Moderate CLE 0.45* 0.43* 0.49* 0.42* 0.41* 0.15
Severe CLE 0.52** 0.39* 0.40* 0.33 0.38* 0.11
Panlobular 0.56** 0.34 0.33 0.29 0.43* 0.22
Paraseptal 0.50** 0.49** 0.46** 0.42* 0.44* 0.12
Non-
emphysema
−0.45* −0.39* −0.41* −0.36* −0.45* −0.44
Spearman’s rho values given
N = 31. *p < 0.05; **p < 0.01
Table 3 Spearman’s correlation analysis between TIMPs and
emphysema sub-types
TIMP-1 TIMP-2 TIMP-3 TIMP-4
Mild CLE −0.04 −0.21 −0.23 −0.18
Moderate CLE 0.03 0.31 0.20 0.37*
Severe CLE 0.05 0.29 0.18 0.36*
Panlobular −0.15 0.22 0.21 0.28
Paraseptal −0.01 0.31 0.24 0.37*
Non-emphysema −0.07 −0.31 −0.19 −0.36*
Spearman’s rho values given
N = 31. *p < 0.05
Table 4 Spearman’s correlation analysis between MMPs/TIMP1
ratios and emphysema sub-types
MMP-3
/TIMP-1
MMP-7
/TIMP-1
MMP-8
/TIMP-1
MMP-9
/TIMP-1
MMP-10
/TIMP-1
MMP-12
/TIMP-1
Mild CLE −0.08 −0.06 −0.05 −0.03 0.01 −0.14
Moderate CLE 0.39* 0.39* 0.44* 0.34 0.43* 0.12
Severe CLE 0.44* 0.36* 0.36* 0.28 0.40* 0.08
Panlobular 0.59*** 0.43* 0.36* 0.31 0.55** 0.33
Paraseptal 0.47** 0.50** 0.42* 0.37* 0.47** 0.15
Normal −0.37* −0.35 −0.36* −0.29 −0.44* −0.04
Spearman’s rho values given
N = 31. *p < 0.05; **p < 0.01; ***p < 0.001
Table 5 Spearman’s correlation analysis between MMPs/TIMP2
ratios and emphysema sub-types
MMP-3
/TIMP-2
MMP-7
/TIMP-2
MMP-8
/TIMP-2
MMP-9
/TIMP-2
MMP-10
/TIMP-2
MMP-12
/TIMP-2
Mild CLE −0.07 −0.09 −0.06 −0.02 0.10 −0.01
Moderate
CLE
0.35 0.22 0.42* 0.27 0.37* −0.05
Severe CLE 0.44* 0.25 0.35 0.23 0.33 −0.10
Panlobular 0.56** 0.32 0.32 0.26 0.46** 0.08
Paraseptal 0.44* 0.34 0.40* 0.31 0.38* −0.04
Normal −0.35 −0.18 −0.34 −0.23 −0.40* 0.13
Spearman’s rho values given
N = 31. *p < 0.05; **p < 0.01
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previously reported that overall emphysema had associ-
ations with MMP-3, -7 and -10 and CT markers of
small airways disease had associations with MMP-3, -7,
-8, -9, -10 and -12 [15]. MMP-9 polymorphisms have
been associated with CLE [10], but ours is the first
study evaluating the contribution of MMPs to different
emphysema sub-types in detail. MMP-3 and -10 had
significant associations with all forms of emphysema
(apart from mild CLE) while MMP-7, -8 and -9 had as-
sociations with multiple sub-types. MMPs are inhibited
by four endogenous inhibitors, the TIMPs which bind
with MMPs in a 1:1 manner [28]. TIMP-3 null mice
develop emphysema [29] while human studies show
TIMP-1 and -2 are raised in the airways of COPD sub-
jects [13, 14, 19, 20] and TIMP-2 polymorphisms are
associated with CLE [10]. We found significantly in-
creased TIMP-2 and TIMP-4 in COPD subjects and
also found that TIMP-4 had positive associations with
several emphysema sub-types. This suggests that
TIMPs are raised in COPD and emphysema although
their activity and specificity are poorly understood. An
imbalance between MMPs and TIMPs may be more
important than absolute concentrations although previ-
ous studies have not demonstrated this [20, 23], or al-
ternatively MMPs may be acting in the immediate
pericellular environment and therefore not inhibited by
TIMPs. In contrast to this previous data, we found a
number of ratios were increased in COPD and a
number had significant associations with emphysema
sub-types.
Perhaps the most interesting results from this study
were those relating to mild CLE. All subjects, irrespect-
ive of whether they had airflow obstruction, had evi-
dence of mild CLE with median values above 30 %. This
is consistent with other studies which have demon-
strated emphysematous change in smokers without air-
flow obstruction [3, 4]. Using LHE CT analysis, Castaldi
also described high rates of mild CLE in healthy
smokers, linking it with degree of airflow obstruction
and functional capacity [2]. This suggests that mild CLE
is a genuine tissue abnormality and occurs prior to the
development of airflow obstruction and a key question is
whether this progresses into more significant disease.
Unlike more severe forms of emphysema we found no
associations between MMPs and mild CLE. When
correcting for the other tissue sub-types, using partial
correlation (data not shown) no associations between
mild CLE and MMPs were found, suggesting mild CLE
genuinely does not have any associations with MMPs.
We propose a possible explanation for this may be that
mild emphysema is ubiquitous in smokers and ex-
smokers and occurs via a non-MMP derived mechanism,
such as oxidative stress secondary to cigarette smoke ex-
posure. It may be that only subjects with significant
MMP activity develop more advanced emphysema and
our results suggest MMP-3 and -10 are the most import-
ant in this process. These MMPs are stromelysins,
mainly degrading collagen and proteoglycans, important
constituents of the pulmonary ECM [22]. In addition
MMP-7, -8 and -9 had associations with moderate CLE
and PSE and MMP-7 and -8 also had associations with
severe CLE. MMP-7 is an elastase, MMP-8 a collagenase
and MMP-9 a gelatinase and together can degrade all
components of the pulmonary ECM [22]. Given that
individual MMPs have different substrate specificity,
it may be proposed that particular MMPs are respon-
sible for each sub-type of emphysema. However, our
results do not support this as the profile of MMP
expression is broadly similar across all emphysema
sub-types, apart from mild CLE. Further mechanistic
work is required to understand this is in more detail
and longitudinal studies are needed to understand
how mild CLE and the other emphysema sub-types
progress and whether this can predicted by MMP
concentrations.
The main limitation of this study was the small sample
size and associated limited statistical power. Despite this
we found strong evidence of associations between
MMPs and emphysema sub-types. Another limitation is
the multiple comparisons made in this study. Excluding
Table 6 Spearman’s correlation analysis between MMPs/TIMP3
ratios and emphysema sub-types
MMP-3
/TIMP-3
MMP-7
/TIMP-3
MMP-8
/TIMP-3
MMP-9
/TIMP-3
MMP-10
/TIMP-3
MMP-12
/TIMP-3
Mild CLE −0.04 0.02 −0.09 0.01 0.14 0.04
Moderate
CLE
0.36* 0.27 0.44* 0.21 0.32 −0.05
Severe CLE 0.40* 0.22 0.32 0.12 0.23 −0.12
Panlobular 0.44* 0.16 0.30 0.13 0.24 −0.04
Paraseptal 0.32 0.27 0.39* 0.17 0.27 −0.13
Normal −0.30 −0.20 −0.33 −0.13 −0.32 0.15
Spearman’s rho values given
N = 31. *p < 0.05
Table 7 Spearman’s correlation analysis between MMPs/TIMP4
ratios and emphysema sub-types
MMP-3
/TIMP-4
MMP-7
/TIMP-4
MMP-8
/TIMP-4
MMP-9
/TIMP-4
MMP-10
/TIMP-4
MMP-12
/TIMP-4
Mild CLE 0.03 −0.02 −0.06 0.03 0.16 0.01
Moderate
CLE
0.35 0.25 0.43* 0.15 0.30 −0.12
Severe CLE 0.41* 0.20 0.32 0.07 0.22 −0.21
Panlobular 0.54** 0.24 0.29 0.11 0.36* 0.01
Paraseptal 0.42* 0.32 0.38* 0.16 0.32 −0.14
Normal −0.35 −0.20 −0.32 −0.09 −0.34 0.21
Spearman’s rho values given
N = 31. *p < 0.05; **p < 0.01
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Table 1, 70 out of 238 comparisons were significant, far
more than the 12 associations expected to be significant
by chance, suggesting genuine associations. Additionally,
all significant results were in the same, expected direc-
tion for each MMP/TIMP and emphysema subtype
comparison. Due to the need to perform bronchoscopy,
our study consisted of patients with mild and moderate
COPD, with only limited amounts of emphysema. It is
unknown whether these results would be similar in a
more severe cohort. Furthermore, the lack of a valid-
ation population limits the generalizability of the find-
ings. Using LHE CT analysis we could only determine
emphysema sub-types throughout the entire lungs rather
than on a lobar basis and further work will involve refin-
ing this analysis to include lobar measurements. How-
ever we have previously shown that comparing BAL
analysis to whole lung CT parameters is a valid tech-
nique [15]. Finally quantitative measures of MMPs and
ratios with TIMPs do not necessarily equate to enzym-
atic activity. We are developing techniques to generate
in-situ zymography data which will be the next step in
understanding the aetiology of emphysema.
Conclusion
In conclusion, mild and moderate CLE were the predom-
inant forms of tissue sub-types measured in a cohort of
mild/moderate COPD subjects. Multiple MMPs were as-
sociated with moderate and severe CLE, paraseptal and
panlobular emphysema. MMP-3 and -10 had associations
with all of these sub-types, suggesting they play an import-
ant part in the tissue destruction seen in these sub-types
of emphysema. Mild CLE was common in both subjects
with COPD and those with preserved lung function and
unlike other tissue sub-types did not have any associations
with MMPs. MMP activity may explain why some subjects
progress to more severe forms of emphysema and in-
creased understanding of these specific mechanisms may
help inform our knowledge of disease progression and
treatment options.
Additional file
Additional file 1: Sensitivity data for MMP and TIMP luminex assays.
MMP/TIMP ratios in BAL in COPD and PLF subjects. (DOCX 171 kb)
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